We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Flow Cytometry Assay Speeds Diagnosis of Pediatric Tuberculosis

By LabMedica International staff writers
Posted on 14 Sep 2014
Epidemiologists working with samples obtained from groups of children in Tanzania, used a novel blood test to quickly diagnose victims of pediatric tuberculosis (TB).

The diagnosis of pediatric tuberculosis is complicated by nonspecific symptoms, difficult specimen collection, and the low number of organisms usually observed in biopsy specimens.

Investigators at the Swiss Tropical and Public Health Institute (Basel, Switzerland) and colleagues at Ludwigs-Maximilians-Universität (Munich, Germany) worked with samples collected from children with symptoms that suggested tuberculosis who had been prospectively recruited at the NIMR-Mbeya Medical Research Center in Mbeya (Tanzania), and the Ifakara Health Institute in Bagamoyo (Tanzania), between May 10, 2011, and September 4, 2012. More...
Sputum and peripheral blood mononuclear cells were obtained for Mycobacterium tuberculosis culture and for performance assessment of the novel TAM-TB blood test.

The TAM-TB assay is based on flow cytometry detection of loss of the CD27 surface marker usually expressed on CD4+ T-cells. This marker disappears after infection of these cells by M. tuberculosis. Results from this assay are available in about 24 hours as compared to results from culture, which require about 20 days.

Among 290 children screened in this study, the investigators selected a subgroup of 130 to ensure testing of at least 20 with culture-confirmed tuberculosis. Of this group of 130, 17 children were excluded because of inconclusive TAM-TB assay results. The TAM-TB assay enabled detection of 15 of 18 culture-confirmed cases (sensitivity 83.3%). Specificity was 96.8% in the 63 cases that were classified as not tuberculosis, with little effect from latent tuberculosis infection. The TAM-TB assay identified five additional patients with highly probable or probable tuberculosis, in whom M. tuberculosis was not isolated.

"This rapid and reliable test has the great potential to significantly improve the diagnosis of active tuberculosis in children," said contributing author Dr. Klaus Reither, TB CHILD Program Manager at the Swiss Tropical and Public Health Institute.

The study was published in the September 1, 2014, online edition of the journal Lancet Infectious Diseases.

Related Links:
Swiss Tropical and Public Health Institute
Ludwigs-Maximilians-Universität


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.